What is the Strategic Fund?
Loading...
Cite
What is the Strategic Fund? (2022). [Information kit (folder, banner, brochure)]. PAHO. https://iris.paho.org/handle/10665.2/55975
Files
English; 2 pages
Date
2022
Document Number
PAHO/HSS/SF/22-0017
ISBN
eISBN
ISSN
DOI
Authors
Description
This advocacy brief provides high-level, clear information for the general public on the PAHO Strategic Fund for Essential Medicines and Supplies.
Notes
Pages
Volume
Replaces
Table of contents
Link to WHO's original document
Series
Link to WHO's original document
Category
Youtube URI
Citation
Status Mendates
License
Related items
Showing items related by metadata.
Item Strategic Fund Annual Report 2019. Improving Access to Quality Medicines and Health Technologies in the Americas(PAHO, 2020)In 2000, the Pan American Health Organization (PAHO) established the Strategic Fund to improve access to safe, efficacious, and high-quality medicines and other health supplies. This increased access would inevitably strengthen the efficiency and sustainability of public health systems in the Americas. The Strategic Fund is a regional technical cooperation mechanism for the pooled procurement of essential medicines and strategic health supplies. The Fund contributes to countries’ commitments to achieving the Sustainable Development Goals (SDGs) by facilitating access to affordable, high-quality medicines, and other health technologies. The 2019 Annual Report of the PAHO Strategic Fund details the progress made possible through close technical cooperation. Because of the Fund’s effectiveness in facilitating enhanced supply chain management of critical public health supplies, we have signed participating agreements with 34 countries and territories and developed new partnerships with pivotal health agencies. Procurement volume through the PAHO Strategic Fund has increased by 81% compared to 2018, proving the Fund is an important mechanism to achieve health for all. Responding to the increasing needs of Member States, the Strategic Fund has negotiated long-term agreements for WHO-prequalified HIV/AIDS and cancer treatments at substantially reduced prices, spearheaded a joint initiative for cardiovascular diseases, and strengthened in-country capacity-building for demand forecasting and inventory management. These initiatives have directly provided treatments for over 7.5 million people in 2018 and 2019 and will enable millions more to access high-quality medicines, diagnostic kits and equipment, vector control materials, and other health supplies and technologies that remain affordable in the coming years.Item Strategic Fund Annual Report 2021: Prioritizing Access to Medicines and Supplies for Health Security and Universal Health(PAHO, 2022)The PAHO Strategic Fund Annual Report 2021 outlines progress made over the past year in helping ensure access to essential medicines and public health supplies while responding to the COVID-19 pandemic, in an effort to strengthen health systems that bridge health security and universal health. The report covers various aspects of the Strategic Fund, including benefits offered, participating stakeholders, product offerings, and key initiatives. It also provides useful data, information, statistics, and examples of ways in which the Strategic Fund has facilitated technical cooperation across the Region of the Americas. This report aims to summarize the critical work undertaken by the Strategic Fund during 2021 and offer insight into its operating principles and goals for long-term strengthening and support of health systems in the Region.Item Strategic Fund. Access to high-quality medicines and health technologies in the Americas. Annual Report 2016(PAHO, 2017)[Preface] Access to medicines and other health supplies is essential if we are to achieve universal access to health and universal health coverage. Rising costs, lack of availability, and substandard quality of medicines constitute some of the challenges that our Member States face in ensuring equitable access to medical products throughout health systems and services. The Strategic Fund was created in 2000 by the Pan American Health Organization (PAHO) as a mechanism to improve equitable access to safe, efficacious, and quality medicines and supplies in the Americas. Through the Strategic Fund, participating countries join together in solidarity to pool needs and collectively procure quality health supplies at affordable prices. The achievements of 2016 reflect the advances that have been made collectively by our Member States as they continue to expand access to medicines and other essential supplies, and move progressively towards the achievement of universal health.Item Strategic Fund Annual Report 2020. Ensuring Access to Essential Medicines and Public Health Supplies while Supporting the COVID-19 Response(PAHO, 2021)The PAHO Strategic Fund Annual Report 2020 outlines progress made over the past year in helping ensure access to essential medicines and public health supplies while responding to the COVID-19 pandemic. The report covers various aspects of the Strategic Fund, including benefits offered, participating stakeholders, product offerings, and key initiatives. It also provides useful data, information, statistics, and examples of ways in which the Strategic Fund has facilitated technical cooperation across the Region of the Americas. This report aims to summarize the critical work undertaken by the Strategic Fund during 2020 and offer insight into its operating principles and goals for long-term strengthening and support of health systems in the Region.Item Essential Medicines for Noncommunicable Diseases Available through the PAHO Strategic Fund(PAHO, 2021)The Pan American Health Organization’s Revolving Fund for Strategic Public Health Supplies (Strategic Fund) helps ensure the availability of essential medicines for noncommunicable diseases, including palliative care medicines, at a competitive price for all countries. The Strategic Fund is an integrated pooled procurement mechanism, and the products purchased through the Strategic Fund meet international standards in safety, efficacy, and quality. This brochure presents information on the medications and their formulations available through the Strategic Fund for noncommunicable diseases, summarized by category: cardiovascular diseases, diabetes, cancer, chronic respiratory diseases, and palliative care. The brochure includes examples of price reductions achieved by the Strategic Fund for key essential medicines, ensuring competitive prices for these for Latin America and the Caribbean.